Today we know that this is largely due to the highly heterogenous nature of tumours both between patients and even within a tumour itself.

Unpredictable treatment responses remain one of oncology's biggest challenges. To truly personalize therapy, we need a deeper view of tumour cell populations, their molecular interactions, and the surrounding microenvironment.

A new study, "Advancing tumour characterization and immune phenotyping through multiomic in situ profiling of RNA and proteins," takes a major step in that direction. By using 10X Genomics' new multiomic assay, Xenium RNA+Protein, the team profiled over 1.7 million cancer cells from human colorectal tumour samples, simultaneously mapping 375 genes and 28 proteins in situ.

By integrating RNA and protein measurements within their native spatial context, they illuminate the complexities of post-transcriptional regulation, sub-cellular localisation, and their combined influence on cancer progression.

Curious to learn more?

BonsaiLab: Your 10x Genomics Partner in Spain and Portugal

As the official distributor of 10x Genomics in Spain and Portugal, BonsaiLab is ready to help you leverage single-cell and spatial genomics in your research.

Contact us and let's arrange a meeting! Get in touch with our experts to explore how Xenium Protein can boost your research.